Janus kinase inhibitors offer targeted treatment for patients with inborn errors of JAK/signal transducer and activator of transcription (STAT) signaling, but data on efficacy and risk for adverse events are limited. New results show promise. https://t.co/Yt4RVE4hzY
To all of us managing #IEI patients with JAK/STAT dysregulation
👉Don ´t miss this latest multinational report of our collective experience with JAKinib treatments
Thank you Marco Fisher, @CS_Freiburg and all co-authors. This is pivotal work👍
https://t.co/S39iR4fDR7
Coming Soon! The New ESID Grand Rounds Webinar on January 24, 2023, at 17:00 (CET), will focus on JAKinh in IEIs of the JAK/STAT pathway. Find out more and register here: https://t.co/bj1xjUFp51
#esid#primaryimmunodeficiency#iei#Immunology